methyl (3S)-4-[tert-butyl(diphenyl)silyl]oxy-3-prop-2-enoxybutanoate | 169940-41-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl (3S)-4-[tert-butyl(diphenyl)silyl]oxy-3-prop-2-enoxybutanoate
• CAS: 169940-41-4
• 化学式: C₂₄H₃₂O₄Si
• 分子量: 412.601
• InChiKey: NNYJQJPBAIQGHF-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (3S)-4-[tert-butyl(diphenyl)silyl]oxy-3-prop-2-enoxybutanoate 在 2,4,6-三甲基吡啶 、 氢氧化钾 、 sodium tetrahydroborate 、 二异丁基氢化铝 、 碳酸氢钠 、 caesium carbonate 、 臭氧 、 三乙胺 、 六甲基二硅氮烷 、 sodium iodide 作用下， 以 四氢呋喃 、 乙醚 、 丙酮 、 甲苯 为溶剂， 反应 29.17h， 生成 C₂₇H₂₂F₃N₃O₆S
  参考文献：
  名称：

  (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno- 1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues:  Isozyme Selective Inhibitors of Protein Kinase Cβ

  摘要：

  Protein kinase C (PKC) is a family of closely related serine and threonine kinases. Overactivation of some PKC isozymes has been postulated to occur in several disease states, including diabetic complications. Selective inhibition of overactivated PKC isozymes may offer a unique therapeutic approach to disease states such as diabetic retinopathy. A novel series of 14-membered macrocycles containing a N-N'-bridged bisindolylmaleimide moiety is described. A panel of eight cloned human PKC isozymes (alpha, beta I, beta II, gamma, delta, epsilon, zeta, eta) was used to identify the series and optimize the structure and associated activity relationship. The dimethylamine analogue LY333531 (1), (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione, inhibits the PKC beta I (IC50 = 4.7 nM) and PKC beta II (IC50 = 5.9 nM) isozymes and was 76- and 61-fold selective for inhibition of PKC beta I and PKC beta II in comparison to PKC alpha, respectively. The additional analogues described in the series are also selective inhibitors of PKC beta. LY333531 (1) exhibits ATP dependent competitive inhibition. of PKC beta I and is selective for PKC in comparison to other ATP dependent kinases (protein kinase A, calcium calmodulin, caesin kinase, src tyrosine kinase). The cellular activity of the series was assessed using bovine retinal capillary endothelial cells. Retinal endothelial cell dysfunction has been implicated in the development of diabetic retinopathy. Plasminogen activator activity stimulated by a phorbol ester (4 beta-phorbol 12,13-dibutyrate) in endothelial cells was inhibited by the compounds in the series with ED(50) values ranging from 7.5 to 0.21 mu M. A comparison of the PKC isozyme and related ATP dependent kinase inhibition profiles is provided for the series and compared to the profile for staurosporine, a nonselective PKC inhibitor. The cellular activity of the series is compared with that of the kinase inhibitor staurosporine.

  DOI：

  10.1021/jm950588y
• 作为产物：
  描述：

  L-苹果酸二甲酯 在 咪唑 、 三氟甲磺酸 、 dimethylsulfide borane complex 作用下， 以 四氢呋喃 、 环己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 80.5h， 生成 methyl (3S)-4-[tert-butyl(diphenyl)silyl]oxy-3-prop-2-enoxybutanoate
  参考文献：
  名称：

  TETRAHYDROBENZOFURODIAZEPINONE COMPOUND AND PHARMACEUTICAL USE THEREOF

  摘要：

  本发明提供了一种具有Pim-1抑制活性的化合物。本发明提供了一种式[I]的化合物或其药学上可接受的盐，含有该化合物的制药组合物，以及其药物用途等。其中，每个符号如描述中所定义。

  公开号：

  US20220162220A1

文献信息

• (<i>S</i>)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno- 1<i>H</i>,13<i>H</i>-dibenzo[<i>e</i>,<i>k</i>]pyrrolo[3,4-<i>h</i>][1,4,13]oxadiazacyclohexadecene-1,3(2<i>H</i>)-dione (LY333531) and Related Analogues:  Isozyme Selective Inhibitors of Protein Kinase Cβ
  作者：Michael R. Jirousek、James R. Gillig、Cecile M. Gonzalez、William F. Heath、John H. McDonald、David A. Neel、Christopher J. Rito、Upinder Singh、Lawrence E. Stramm、Anita Melikian-Badalian、Matthew Baevsky、Lawrence M. Ballas、Steven E. Hall、Leonard L. Winneroski、Margaret M. Faul

  DOI：10.1021/jm950588y

  日期：1996.1.1

  Protein kinase C (PKC) is a family of closely related serine and threonine kinases. Overactivation of some PKC isozymes has been postulated to occur in several disease states, including diabetic complications. Selective inhibition of overactivated PKC isozymes may offer a unique therapeutic approach to disease states such as diabetic retinopathy. A novel series of 14-membered macrocycles containing a N-N'-bridged bisindolylmaleimide moiety is described. A panel of eight cloned human PKC isozymes (alpha, beta I, beta II, gamma, delta, epsilon, zeta, eta) was used to identify the series and optimize the structure and associated activity relationship. The dimethylamine analogue LY333531 (1), (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione, inhibits the PKC beta I (IC50 = 4.7 nM) and PKC beta II (IC50 = 5.9 nM) isozymes and was 76- and 61-fold selective for inhibition of PKC beta I and PKC beta II in comparison to PKC alpha, respectively. The additional analogues described in the series are also selective inhibitors of PKC beta. LY333531 (1) exhibits ATP dependent competitive inhibition. of PKC beta I and is selective for PKC in comparison to other ATP dependent kinases (protein kinase A, calcium calmodulin, caesin kinase, src tyrosine kinase). The cellular activity of the series was assessed using bovine retinal capillary endothelial cells. Retinal endothelial cell dysfunction has been implicated in the development of diabetic retinopathy. Plasminogen activator activity stimulated by a phorbol ester (4 beta-phorbol 12,13-dibutyrate) in endothelial cells was inhibited by the compounds in the series with ED(50) values ranging from 7.5 to 0.21 mu M. A comparison of the PKC isozyme and related ATP dependent kinase inhibition profiles is provided for the series and compared to the profile for staurosporine, a nonselective PKC inhibitor. The cellular activity of the series is compared with that of the kinase inhibitor staurosporine.
• TETRAHYDROBENZOFURODIAZEPINONE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：US20220162220A1

  公开（公告）日：2022-05-26

  The present invention provides a compound having a Pim-1 inhibitory activity. The present invention provides a compound of Formula [I] or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same, and a pharmaceutical use thereof, and the like. wherein each symbol is as defined in the description.

  本发明提供了一种具有Pim-1抑制活性的化合物。本发明提供了一种式[I]的化合物或其药学上可接受的盐，含有该化合物的制药组合物，以及其药物用途等。其中，每个符号如描述中所定义。